Home > Formulary : Adult > Recent Decisions > 2017 >
Decisions 17th January 2017
At the meeting that took place on 17th January, the following decisions were agreed:
New Drug Requests
Approved
Alogliptin
- To be added with Prescribing advice for Gliptins
Degludec Type 1
- SCP to be discussed at the next JFG meeting
Fexofenadine
- Fexofenadine is for the treatment of chronic idiopathic urticaria and seasonal allergic rhinitis in patients who have not adequately responded to cetirizine and loratadine. Fexofenadine is more expensive than loratadine and cetirizine
Not Approved
Degludec Type 2
- No changes are required to the current status
Shared Care Protocols/TLS Change in Status
Adjuvant bisphosphonates in Early Breast Cancer
- SCP to be circulated via email
Goserelin and triptorelin
- The group felt that GPs would not initiate this drug and that it should remain Amber, but could move to no shared care to reflect that no particular monitoring is needed by primary care
Melatonin
- In adults initiated by a Neuropsychiatrist
- The group felt that this was originally added to the formulary approximately 9 years ago before establishment of the Joint Formulary. MP agreed that NBT would review use of Melatonin for this indication and report back to the group.